2 withdrawn. 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Withdrawn 2 |
Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases LCAR-AIO T cells - Relapsed/Refractory Autoimmune Diseases | Early Phase 1 | Withdrawn | Nanjing Legend Biotech Co. | 2025-06-17 | 2025-07-08 | |
| Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease hyaluronidase injected intradermally - Microstomia, Scleroderma | Early Phase 1 | Withdrawn | Brigham and Women's Hospital | 2020-01-01 | 2021-01-14 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Autoimmune Diseases (1) · CREST Syndrome (1) · Lupus Erythematosus, Systemic (1) · Microstomia (1) · Myositis (1) · Recurrence (1) · Scleroderma, Diffuse (1) · Scleroderma, Localized (1) · Scleromyxedema (1)
Cardiovascular Diseases (2) · Connective Tissue Diseases (2) · Skin Diseases (2) · Skin Diseases, Vascular (2) · Skin and Connective Tissue Diseases (2) · Vascular Diseases (2) · Calcinosis (1) · Calcium Metabolism Disorders (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Deglutition Disorders (1) · Digestive System Diseases (1) · Disease Attributes (1) · Embolism and Thrombosis (1) · Esophageal Diseases (1)
Brigham and Women's Hospital (1) · Nanjing Legend Biotech Co. (1)
China (1)